Global Postmenopausal Osteoporosis Treatment Market Opportunities 2024, Forecast To 2033
8 Mar, 2024
The postmenopausal osteoporosis treatment market expanded from $9.49 billion in 2023 to $10.03 billion in 2024, with a CAGR of 5.7%. Projected to grow to $12.38 billion in 2028, fueled by precision medicine and digital health integration.
Global Postmenopausal Osteoporosis Treatment Market Key Driver
The postmenopausal osteoporosis treatment market is set to expand due to the increasing prevalence of osteoporosis. Fractures caused by osteoporosis have risen, indicating a growing need for treatment. Therefore, the rising prevalence of osteoporosis drives the growth of the postmenopausal osteoporosis treatment market.
Get A Free Sample Of The Global Postmenopausal Osteoporosis Treatment Market ReportGlobal Postmenopausal Osteoporosis Treatment Market Segments
The postmenopausal osteoporosis treatment market covered in this report is segmented –
1) Drug Type:Bisphosphonates, Vitamin D3, Estrogen Agonist Or Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Other Drug Types
2) Route Of Administration:Oral, Parenteral, Other Routes Of Administration
3) Distribution Channel:Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
By Geography: The countries covered in the postmenopausal osteoporosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the postmenopausal osteoporosis treatment market in 2023. The regions covered in the postmenopausal osteoporosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Postmenopausal Osteoporosis Treatment Industry Players
Pfizer Inc.; Johnson and Johnson; F. Hoffmann-La Roche AG; Merck and Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi SA; Eli Lilly and Company; Amgen Inc.; Asahi Kasei Corporation; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Sandoz International GmbH; Fresenius Kabi AG; Daiichi Sankyo Company Ltd.; Sun Pharmaceutical Industries Ltd.; Cipla Inc.; Dr.Reddys Laboratories Ltd.; Hikma Pharmaceuticals PLC.; Amneal Pharmaceuticals LLC; Zydus Lifesciences Ltd.; Takeda Pharmaceutical Company Limited; Lupin Limited; Celltrion Inc.; Biocon Limited; Accord Healthcare Ltd; Ligand Pharmaceuticals Incorporated; Torrent Pharmaceuticals Limited.
Get The Full Global Postmenopausal Osteoporosis Treatment Market Report
Postmenopausal Osteoporosis Treatment Market Overview
Postmenopausal osteoporosis treatment refers to medical interventions and strategies to manage and prevent bone loss and fractures in women after menopause. Postmenopausal osteoporosis is characterized by decreased bone density and increased susceptibility to fractures due to hormonal changes after menopause.